Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Omeros Corporation
SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a replacement universal shelf registration statement (the "2013 Registration Statement") with the Securities and Exchange Commission (the "SEC"). The 2013 Registration Statement was filed as routine course of business due to the impending expiration of the company's existing universal shelf registration statement (the "2010 Registration Statement") that, under SEC rules, would have expired on Friday, October 18, 2013. Pursuant to SEC rules, the expiration date of the 2010 Registration Statement has been extended until the earlier of the effective date of the 2013 Registration Statement or April 16, 2014. Upon effectiveness, the company may use the 2013 Registration Statement to offer and sell common and preferred stock, debt securities and other securities having an aggregate offering amount of no more than $100 million, which is the amount that was registered under the 2010 Registration Statement. The 2013 Registration Statement, once it becomes effective, will continue to provide the company with flexibility to access the public capital markets in response to financing and business opportunities that may arise from time to time over its expected three-year term. No sales will occur under the 2013 Registration Statement prior to the time it becomes effective.
This press release is neither an offer to sell nor the solicitation of an offer to buy any securities and shall not constitute an offer or solicitation in any jurisdiction where such offer or solicitation is unlawful.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system.
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
©2012 PR Newswire. All Rights Reserved.